Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mistras Group Inc

9.32
+0.05000.54%
Post-market: 9.320.00000.00%16:07 EDT
Volume:128.28K
Turnover:1.19M
Market Cap:289.22M
PE:15.53
High:9.37
Open:9.24
Low:9.13
Close:9.27
Loading ...

Securitize acquires MG Stover’s fund services unit, becoming the largest digital asset fund administrator 5 seconds ago

cryptonews
·
16 Apr

Asset Tokenization Platform Securitize Acquires Division of MG Stover & Co., Asset Under Management Reaches $38 Billion

Blockbeats
·
16 Apr

Press Release: Securitize Acquires MG Stover's Fund Administration Business to Become the Largest Digital Asset Fund Administrator

Dow Jones
·
16 Apr

Press Release: MISTRAS Group Names Aerospace & Defense Leader Cliff Schaffer as SVP of In-Lab Services

Dow Jones
·
14 Apr

Owning 44% shares,institutional owners seem interested in Mistras Group, Inc. (NYSE:MG),

Simply Wall St.
·
10 Apr

NYSE Content Advisory: Pre-Market update + NYSE-listed Delta Air Lines reports earnings

CNW Group
·
09 Apr

MISTRAS Group Rings Bell at NYSE, Reaffirming Its Leadership in Data-Driven Asset Protection

GlobeNewswire
·
09 Apr

China-owned British car brand MG aims to double South-east Asia sales to 100,000 in next three years

businesstimes
·
09 Apr

Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

GlobeNewswire
·
08 Apr

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

GlobeNewswire
·
27 Mar

New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

PR Newswire
·
26 Mar

Brazil Potash Announces Participation In Diversibram 2025

GlobeNewswire
·
26 Mar

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib

Zacks
·
25 Mar

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success

Zacks
·
20 Mar

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

Benzinga
·
20 Mar

Immunovant’s Batoclimab Shows Promising Efficacy in MG and CIDP, Justifying Buy Rating

TIPRANKS
·
20 Mar

Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright

TIPRANKS
·
20 Mar

Roivant says Immunovant announces results from Phase 3 study of batoclimab in MG

TIPRANKS
·
19 Mar

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

GlobeNewswire
·
19 Mar

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

GlobeNewswire
·
19 Mar